AKRO Stock Summary and Trading Ideas (Akero Therapeutics | NASDAQ:AKRO)

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics trades on the NASDAQ stock market under the symbol AKRO.

As of October 4, 2024, AKRO stock price climbed to $28.24 with 520,979 million shares trading.

AKRO has a beta of 2.11, meaning it tends to be more sensitive to market movements. AKRO has a correlation of 0.04 to the broad based SPY ETF.

AKRO has a market cap of $1.96 billion. This is considered a Small Cap stock.

In the last 3 years, AKRO traded as high as $58.38 and as low as $7.52.

The top ETF exchange traded funds that AKRO belongs to (by Net Assets): VTI, IWM, VXF, XBI, IWN.

AKRO has underperformed the market in the last year with a price return of -38.7% while the SPY ETF gained +36.6%. However, in the short term, AKRO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +28.8% vs +4.2% return in SPY. But in the last 2 weeks, AKRO shares have been beat by the market, returning +0.6% compared to an SPY return of +0.8%.

AKRO support price is $26.75 and resistance is $28.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKRO shares will trade within this expected range on the day.